参考文献

1.Enewold L，Zhu K，Ron E，et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics，1980-2005. Cancer Epidemiol Biomarkers Prev，2009，18：784-791.

2.Guan H，Ji M，Bao R，et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab，2009，94：1612-1617.

3.Loupakis F，Ruzzo A，Cremolini C，et al. KRAS codon 61，146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer，2009，101：715-721.

4.Franklin WA，Haney J，Sugita M，et al. KRAS mutation：comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn，2010，12：43-50.

5.Zou M，Baitei EY，Alzahrani AS，et al. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Neoplasia，2009，11：57-65.

6.Wells SA Jr，Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res，2009，15：7119-7123.

7.Greco A，Miranda C，Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol，2010，321：44-49.

8.Giusti F，Falchetti A，Franceschelli F，et al. Thyroid cancer：current molecular perspectives. J Oncol，2010，351：679.

9.Sadow PM，Heinrich MC，Corless CL，et al. Absence of BRAF，NRAS，KRAS，HRAS，mutations，and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol，2010，21：73-79.

10.Smallridge RC，Copland JA. Anaplastic thyroid carcinoma：pathogenesis and emerging therapies. Clin Oncol，2010，22：486-497.

11.Parameswaran R，Brooks S，Sadler GP. Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg，2010，8：186-193.

12.Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid，2010，20：697-706.

13.Sheu SY，Vogel E，Worm K，et al. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology，2010，56：632-640.